603739.SH
蔚蓝生物
SSE · Healthcare · Biotechnology · CN
CNY 12.05
−1.95%Year over year
Reported trailing growth
- Revenue
- +4.2%
- EBITDA
- —
- EBIT
- +7.3%
- EPS
- +28.8%
- Free cash flow
- -19.0%
- Operating cash flow
- -42.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.5%
- EBITDA
- +13.2%
- EBIT
- +7.4%
- Net income
- -0.0%
- EPS
- +0.0%
- Free cash flow
- -62.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026